Featured Research

from universities, journals, and other organizations

Key genes that switch off with aging highlighted as potential targets for anti-aging therapies

Date:
April 19, 2012
Source:
King's College London
Summary:
Researchers have identified a group of "aging" genes that are switched on and off by natural mechanisms called epigenetic factors, influencing the rate of healthy aging and potential longevity.

Researchers have identified key genes that switch off with aging, highlighting them as potential targets for anti-aging therapies.
Credit: Sandor Kacso / Fotolia

Researchers have identified key genes that switch off with aging, highlighting them as potential targets for anti-aging therapies.

Researchers at King's College London, in collaboration with the Wellcome Trust Sanger Institute, have identified a group of 'aging' genes that are switched on and off by natural mechanisms called epigenetic factors, influencing the rate of healthy aging and potential longevity.

The study also suggests these epigenetic processes -- that can be caused by external factors such as diet, lifestyle and environment -- are likely to be initiated from an early age and continue through a person's life. The researchers say that the epigenetic changes they have identified could be used as potential 'markers' of biological aging and in the future could be possible targets for anti-aging therapies.

Published April 20 in PLoS Genetics, the study looked at 172 twins aged 32 to 80 from the TwinsUK cohort based at King's College London and St Thomas' Hospital, as part of King's Health Partners Academic Health Sciences Centre.

The researchers looked for epigenetic changes in the twins' DNA, and performed epigenome-wide association scans to analyze these changes in relation to chronological age. They identified 490 age related epigenetic changes. They also analysed DNA modifications in age related traits and found that epigenetic changes in four genes relate to cholesterol, lung function and maternal longevity.

To try to identify when these epigenetic changes may be triggered, the researchers replicated the study in 44 younger twins, aged 22 to 61, and found that many of the 490 age related epigenetic changes were also present in this younger group. The researchers say these results suggest that while many age related epigenetic changes happen naturally with age throughout a person's life, a proportion of these changes may be initiated early in life.

Dr Jordana Bell from King's College London, who co-led the study said: 'We found that epigenetic changes associate with age related traits that have previously been used to define biological age.

'We identified many age-related epigenetic changes, but four seemed to impact the rate of healthy aging and potential longevity and we can use these findings as potential markers of aging. These results can help understand the biological mechanisms underlying healthy aging and age-related disease, and future work will explore how environmental effects can affect these epigenetic changes.'

Dr Panos Deloukas, co-leader of the study from the Wellcome Trust Sanger Institute, said: 'Our study interrogated only a fraction of sites in the genome that carry such epigenetic changes; these initial findings support the need for a more comprehensive scan of epigenetic variation.'

Professor Tim Spector, senior author from King's College London, said: 'This study is the first glimpse of the potential that large twin studies have to find the key genes involved in aging, how they can be modified by lifestyle and start to develop anti-aging therapies. The future will be very exciting for age research.'


Story Source:

The above story is based on materials provided by King's College London. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jordana T. Bell, Pei-Chien Tsai, Tsun-Po Yang, Ruth Pidsley, James Nisbet, Daniel Glass, Massimo Mangino, Guangju Zhai, Feng Zhang, Ana Valdes, So-Youn Shin, Emma L. Dempster, Robin M. Murray, Elin Grundberg, Asa K. Hedman, Alexandra Nica, Kerrin S. Small, Emmanouil T. Dermitzakis, Mark I. McCarthy, Jonathan Mill, Tim D. Spector, Panos Deloukas. Epigenome-Wide Scans Identify Differentially Methylated Regions for Age and Age-Related Phenotypes in a Healthy Ageing Population. PLoS Genetics, 2012; 8 (4): e1002629 DOI: 10.1371/journal.pgen.1002629

Cite This Page:

King's College London. "Key genes that switch off with aging highlighted as potential targets for anti-aging therapies." ScienceDaily. ScienceDaily, 19 April 2012. <www.sciencedaily.com/releases/2012/04/120419191709.htm>.
King's College London. (2012, April 19). Key genes that switch off with aging highlighted as potential targets for anti-aging therapies. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/04/120419191709.htm
King's College London. "Key genes that switch off with aging highlighted as potential targets for anti-aging therapies." ScienceDaily. www.sciencedaily.com/releases/2012/04/120419191709.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins